This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cardiologists have long known that platelets can become "hyperreactive" to cause abnormal clotting that blocks arteries and contributes to heartattack, stroke, and poor blood flow (peripheralarterydisease) in the legs of millions of Americans.
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheralarterydisease is essential to improve outcomes and reduce amputation risk, heartattack, stroke and death for people with PeripheralArteryDisease (PAD).
Patient Demographics: Patients on APT had a higher rate of coronary arterydisease (70% vs. 42%), previous heartattacks (36% vs. 16%), and peripheralarterydisease (15% vs. 11%). For more information, please visit anthostherapeutics.com.
The global burden of peripheralarterydisease. Decline in functional performance predicts later increased mobility loss and mortality in peripheralarterialdisease. J Am Heart Assoc. The global burden of peripheralarterydisease. J Vasc Surg. 2023;77:1119-26. J Am Coll Card.
Having a heartattack significantly increases the risk of developing other serious long-term health conditions, a major new study shows. Up to a third of patients went on to develop heart or kidney failure, 7% had further heartattacks and 38% died from any cause within the nine-year study period.
A study in the Journal of Vascular Surgery revealed that adding FFRCT assessments to patient workups prior to peripheralarterydisease surgeries has a massive impact on coronary arterydisease detection, treatments, and long-term outcomes.
The study aims to evaluate the applicability in the real world of randomised clinical trials (RCT) on antithrombotic treatment in patients with cardiovascular disease (CVD) and peripheralarterydisease (PAD).
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary arterydisease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
The Shockwave E 8 catheter is designed to optimize the treatment of patients with calcified femoro-popliteal and below-the-knee peripheralarterydisease (PAD), including patients with complex chronic limb-threatening ischemia (CLTI). PAD affects more than eight million people aged 40 and older in the United States.
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary arterydisease (CAD) and peripheralarterydisease (PAD).
According to a recent survey released today by the Society, nearly one in three Americans at the highest risk for developing blood vessel (vascular) diseases have not heard of any of the most common conditions, like peripheralarterydisease and carotid arterydisease.
Methods Inclusion and exclusion criteria of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS), Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA), Prevention of Cardiovascular events in Patients with Prior HeartAttack Using Ticagrelor Compared to Placebo on a Background (..)
years of age, P <0.001), cerebral or peripheralarterydisease (6.2% There may be no better study to symbolize the dysfunction that has invaded cardiology than the VIRGO trial, a study examining the outcomes of young patients (18-55) presenting to the hospital with a heartattack. years of age versus 59.0±8.4
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content